Screener
Intellia Therapeutics NTLA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -711.7%+257pp | -636.6%+551pp | -651.7%+271pp | -832.2%+363pp | -968.7%+126pp | |
| Net margin | -672.2%+236pp | -597%+557pp | -609.9%+287pp | -774.9%+386pp | -908.5%+154pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.6×+1.5× | 6.1×+1.2× | 5.1×-0.7× | 6.2×-0.5× | 5.2×-2.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×— | 0.1×0.0× | 0.1×-0.1× | 0.1×0.0× | —— | |
| Per Share | ||||||
| Book value per share | $5.45+179% | $5.24-30.5% | $6.20-29.8% | $6.79-28.7% | -$6.90-169% | |
| Valuation | ||||||
| Market capitalization | $1.57B+33.3% | $1.51B+106% | $1.04B-12.3% | $1.85B-7.0% | $991.29M-53.6% | |
| Price / sales | 26.4×+4.1× | 22.9×+6.8× | 15.4×-5.1× | 32.2×-12.1× | 18.8×-25.9× | |
| Price / book | 2.2×— | 2.4×+1.5× | 1.6×+0.2× | 2.5×+0.4× | —— |
FAQ
- Where do Intellia Therapeutics's ratios come from?
- Every ratio is computed from Intellia Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
